Former Trump HHS Secretary Alex Azar is taking issue with a Biden administration program for negotiating lower Medicare drug prices with pharmaceutical companies, calling the effort “price fixing” and a danger to innovation.
Azar’s remarks came during a Monday session at Milken’s 2023 Future of Health Summit in which he and President Joe Biden’s Health and Human Services secretary, Xavier Becerra, discussed drug pricing, mental health, Covid-19, and other leading health topics.
Created under 2022’s Inflation Reduction Act, the drug price negotiation program has spurred widespread pharmaceutical industry backlash. Drugmakers and industry groups have filed a slew of lawsuits to ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.